About five years ago, I ran into a problem many people face as they get older: The people I holiday shop for typically just buy everything they want throughout the year. That, of course, left me ...

Angelica Leicht is a seasoned personal finance writer and editor with nearly two decades of experience but just one goal: to help readers make the best decisions for their wallets. Her expertise spans ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

A reverse mortgage allows seniors to access cash from the equity they've built up in their homes. Unlike home equity loans or HELOCs, there's usually no credit score requirement and you don't have to ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

December 19, 2025: We added two new Reverse 1999 codes for free Clear Drops. What are the new Reverse 1999 codes? If you're making a start in Bluepoch's strategic RPG, you're probably burning through ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting, ...

First, a few apologies. You will have seen little mention in these pages of arguably the most significant cinematic phenomenon of 2025. Ne Zha 2, a Chinese animated epic, did open (very quietly) in ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› by Kit Dillon We love the look ...

Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. Thomas J. Brock is a CFA and CPA with more than 20 ...